



Toward Smarter Drug Regulation The Case for Cross-Border Data Sharing

Kurt Kammerer, kurt@datavaccinator.com



The Promise of Cross-border Exchange of Drug Data





Better outcome for patients in the era of tighter healthcare budgets.


- Higher Effectiveness
- Broader Availability
- Respecting Budget Constraints

Affordable access to AI-ready Health Data is imperative and will further improve as regional approaches to data supplement purely national ones.

Legislation on Cross-Border Health Data Exchange



Figure 2. Data protection and privacy legislation worldwide



Source: UNCD, Data Protection and Privacy Legislation Worldwide (2021). https://unctad.org/page/data-protection-and-privacy-legislation-worldwide

Source: Himms.org

The In-transparent International Drug Market





The Truth Behind International Drug Pricing

https://globalmarketingprofessor.com/the-truth-behindinternational-drug-pricing/

Complex negotiation structures

- Ineffective price controls Disincentives to keep cost low
- Supply & Demand Volatility
- Patent issues

Challenges: Drug Prices, Availability and Effectiveness



GPs and pharmacists call for action on volatile drug costs as prescribing bill spirals

GPs and pharmacists have called for action to tackle volatile drug costs after a £500m surge in prescribing spending in 2023/24, with spending on some medications more than doubling.

by Nick Bostock




Source: **GPonline**

Spending on Drugs: Discrepancies across Europe



Prescription medicine costs across Europe


Annual spending per capita on retail drugs



How Europeans pay for medicines

All retail drugs, not only prescriptions

Government or mandatory schemes Voluntary health insurance
Out-of-pocket payments Other




Source: OECD's Health at a Glance: Europe 2024 • Data from 2022

Source: OECD's Health at a Glance: Europe 2024 • Data from 2022

How to make Drug Data "Al-ready"





Source: Researchgate.net

Lack of Real-World Data >> Go Synthetic ?!?





SYNTHETIC DATA IN HEALTHCARE




Figure 1. The Synthetic Data Lifecycle: From Ethical Sourcing to Responsible Reuse

Source: <u>Synthetic Data in Healthcare</u>

The Promise of Synthetic Data





SYNTHETIC DATA IN HEALTHCARE



Figure 1. The Synthetic Data Lifecycle: From Ethical Sourcing to Responsible Reuse

From Gaps to Gains: Using Synthetic Data to Improve Al Fairness

High-performing healthcare AI requires large, diverse and representative datasets, something that real-world clinical data often fails to deliver. SD closes these gaps by augmenting datasets with rare conditions, catering for balanced class distributions and greater demographic variability.

Source: Synthetic Data in Healthcare

The Promise of Synthetic Data





From Gaps to Gains: Using Synthetic Data to Improve Al Fairness

High-performing healthcare AI requires large, diverse and representative datasets, something that real-world clinical data often fails to deliver. SD closes these gaps by augmenting datasets with rare conditions, catering for balanced class distributions and greater demographic variability.

Source: Synthetic Data in Healthcare

MENA Cross-Border Data Exchange >> Al-ready Data at Scale






Fig.: DCO.org Sovereign Data Ecosystems with multiple service providers (SP: any data, any DC, any transport channel), connected via Clearing

Cross-Border Drug Data for MENA




MENA Drug Price Board

Search drugs by name or active ingredient

Q trade name, active ingredient or exact register number

I-PROFEN 400MG TABLET





Date	Saudi Arabia	Cyprus	Country 3	Country 4
2024-12-01	\$2.68	\$2.67	\$2.71	\$2.68
2024-12-31	\$2.65	\$2.69	\$2.68	\$2.68
2025-01-30	\$2.71	\$2.67	\$2.72	\$2.68
2025-03-02	\$2.70	\$2.66	\$2.71	\$2.67
2025-03-29	\$2.69	\$2.66	\$2.71	\$2.65
2025-04-28	\$2.66	\$2.65	\$2.73	\$2.70
2025-05-30	\$2.70	\$2.66	\$2.68	\$2.66
2025-06-29	\$2.65	\$2.63	\$2.70	\$2.66
2025-07-29	\$2.67	\$2.68	\$2.69	\$2.66
2025-08-28	\$2.70	\$2.65	\$2.68	\$2.68
2025-09-28	\$2.67	\$2.65	\$2.69	\$2.70
2025-10-27	\$2.70	\$2.68	\$2.70	\$2.67

This data is for demonstration purpose only. No liability, no warranties.

Trade Name: I-PROFEN 400MG TABLET

Scientific Name: IBUPROFEN

Marketing Company: KUWAIT SAUDI PHARMACEUTICAL INDUSTRIES

Marketing Country: Kuwait

Manufacturer: KUWAIT SAUDI PHARMACEUTICAL INDUSTRIES

Manufact. Country: Kuwait Register N°: 2811246349

ATC Code: M01AE01

Pharmaceutical Form: Tablet Package Types: Blister

Package Size: 30

Size: -Size Unit: -

Distribute Area: Pharmacy

Description Code: 7000000647-400-100000073664

Let's stay in touch.



Thank you.

slides at https://datavaccinator.com/news.html

Kurt Kammerer, CEO https://www.linkedin.com/in/kammererkurt/

DataVaccinator SARL

7, route d'Esch L-1470 Luxembourg Luxembourg **DataVaccinator Limited**

VD, 1st floor Masdar City, Abu Dhabi United Arab Emirates **DataVaccinator LLC**

Riyadh, KSA

DataVaccinator



DataVaccinator (DV) powers Data Ecosystems. By "vaccinating data against abuse", DV solutions protect sensitive data, enable secure collaboration and ensure Data Sovereignty in AI environments. DV products rely on its unique technologies (60 patents).

As partner in major initiatives, DV provides guidance on cyber security, governance, compliance, setup and operation of AI-ready data networks.

Background and Expertise:

- Deep Technical Know-how in secure Collaboration and Ecosystems
- Intellectual Property Rights (IPR): Assessment and Management
- Data Ecosystems: Healthcare in EU/MENA, Secure Supply Chains (WEF),
 Belt&Road (Asia), Logistics (Air, Sea, Road), Cyber Security (ASEAN)
- Belfer Security Center (Harvard, JFK), WEF Security Group